Lipoplex-based targeted gene therapy for the suppression of tumours with VEGFR expression by producing anti-angiogenic molecules

BACKGROUND: The anti-angiogenic fusion protein RBDV-IgG1 Fc (RBDV), which comprises the receptor-binding domain of vascular endothelial growth factor-A (VEGF-A), has shown antitumour effects by reducing angiogenesis in vivo. This study used the cationic lipoplex lipo-PEG-PEI-complex (LPPC) to simult...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Nanobiotechnology
Autors principals: Ho, Shu-Yi, Chen, Pin-Rong, Chen, Chia-Hung, Tsai, Nu-Man, Lin, Yu-Hsin, Lin, Chen-Si, Chuang, Cheng-Hsun, Huang, Xiao-Fan, Chan, Yi-Lin, Liu, Yen-Ku, Chung, Chen-Han, Weng, Shun-Long, Liao, Kuang-Wen
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7144055/
https://ncbi.nlm.nih.gov/pubmed/32272948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12951-020-00610-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars